Bayesian Methods in Pharmacovigilance

Regulators such as the U.S. Food and Drug Administration have elaborate, multi-year processes for approving new drugs as safe and effective. Nonetheless, in recent years, several approved drugs have been withdrawn from the market because of serious and sometimes fatal side effects. We describe statistical methods for post-approval data analysis that attempt to detect drug safety problems as quickly as possible. Bayesian approaches are especially useful because of the high dimensionality of the data, and, in the future, for incorporating disparate sources of information.

[1]  Alexander M Walker,et al.  Signal detection for vaccine side effects that have not been specified in advance , 2010, Pharmacoepidemiology and drug safety.

[2]  K. Belton,et al.  Attitude survey of adverse drug-reaction reporting by health care professionals across the European Union , 1997, European Journal of Clinical Pharmacology.

[3]  Robert L Davis,et al.  Real-Time Vaccine Safety Surveillance for the Early Detection of Adverse Events , 2007, Medical care.

[4]  David Madigan,et al.  Large-Scale Bayesian Logistic Regression for Text Categorization , 2007, Technometrics.

[5]  David Madigan,et al.  Pooled analysis of rofecoxib placebo-controlled clinical trial data: lessons for postmarket pharmaceutical safety surveillance. , 2009, Archives of internal medicine.

[6]  Sebastian Schneeweiss,et al.  A basic study design for expedited safety signal evaluation based on electronic healthcare data , 2010, Pharmacoepidemiology and drug safety.

[7]  David Madigan,et al.  Large-scale regression-based pattern discovery: The example of screening the WHO global drug safety database , 2010 .

[8]  William DuMouchel,et al.  Bayesian Data Mining in Large Frequency Tables, with an Application to the FDA Spontaneous Reporting System , 1999 .

[9]  H. Morgenstern,et al.  Confounding in health research. , 2001, Annual review of public health.

[10]  A. Bate,et al.  A Bayesian neural network method for adverse drug reaction signal generation , 1998, European Journal of Clinical Pharmacology.

[11]  Chih-Jen Lin,et al.  A Comparison of Optimization Methods and Software for Large-scale L1-regularized Linear Classification , 2010, J. Mach. Learn. Res..

[12]  D. G. Simpson,et al.  The Statistical Analysis of Discrete Data , 1989 .

[13]  S. Cessie,et al.  Ridge Estimators in Logistic Regression , 1992 .

[14]  C P Farrington,et al.  Relative incidence estimation from case series for vaccine safety evaluation. , 1995, Biometrics.

[15]  M. Maclure.  The case-crossover design: a method for studying transient effects on the risk of acute events. , 1991, American journal of epidemiology.

[16]  J. Roy,et al.  Conditional Inference Methods for Incomplete Poisson Data With Endogenous Time-Varying Covariates , 2006 .

[17]  William DuMouchel,et al.  Empirical bayes screening for multi-item associations , 2001, KDD '01.

[18]  J. Avorn,et al.  High-dimensional Propensity Score Adjustment in Studies of Treatment Effects Using Health Care Claims Data , 2009, Epidemiology.

[19]  C. Paddy Farrington,et al.  Within‐individual dependence in self‐controlled case series models for recurrent events , 2010 .

[20]  Lingling Li,et al.  A conditional sequential sampling procedure for drug safety surveillance , 2009, Statistics in medicine.

[21]  G. Niklas Norén,et al.  Temporal pattern discovery for trends and transient effects: its application to patient records , 2008, KDD.

[22]  Communication of findings in pharmacovigilance: use of the term “signal” and the need for precision in its use , 2005, European Journal of Clinical Pharmacology.

[23]  D. Madigan,et al.  The role of data mining in pharmacovigilance , 2005, Expert opinion on drug safety.

[24]  H. Friedl.  Econometric Analysis of Count Data , 2002 .

[25]  R. Tibshirani.  Regression Shrinkage and Selection via the Lasso , 1996 .

[26]  Heather J Whitaker,et al.  Case series analysis for censored, perturbed, or curtailed post-event exposures. , 2008, Biostatistics.

[27]  John P. Mullooly,et al.  Comparison of epidemiologic methods for active surveillance of vaccine safety. , 2008, Vaccine.

[28]  Richard Solomon,et al.  Contrast Media and Nephropathy: Findings From Systematic Analysis and Food and Drug Administration Reports of Adverse Effects , 2006, Investigative radiology.

[29]  A. Hoes,et al.  Non-sedating antihistamine drugs and cardiac arrhythmias -- biased risk estimates from spontaneous reporting systems? , 2002, British journal of clinical pharmacology.

[30]  I. Ralph Edwards,et al.  Principles of Signal Detection in Pharmacovigilance , 1997, Drug safety.

[31]  J. Rassen,et al.  Confounding Control in Healthcare Database Research: Challenges and Potential Approaches , 2010, Medical care.

[32]  Jeffrey R Curtis,et al.  Adaptation of Bayesian Data Mining Algorithms to Longitudinal Claims Data: Coxib Safety as an Example , 2008, Medical care.

[33]  Jie Chen,et al.  Mining Unexpected Temporal Associations: Applications in Detecting Adverse Drug Reactions , 2008, IEEE Transactions on Information Technology in Biomedicine.

[34]  J. T. Wulu,et al.  Regression analysis of count data , 2002 .

[35]  Richard Platt,et al.  Early adverse drug event signal detection within population‐based health networks using sequential methods: key methodologic considerations , 2009, Pharmacoepidemiology and drug safety.

[36]  M. Kulldorff,et al.  A Maximized Sequential Probability Ratio Test for Drug and Vaccine Safety Surveillance , 2011 .

[37]  J. Wooldridge.  Distribution-free estimation of some nonlinear panel data models , 1999 .